Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist, produces significantly greater body weight reduction (up to 20.9% at 15mg) compared to semaglutide and other GLP-1 agonists in patients with obesity, with real-world studies confirming superior efficacy.
Tirzepatide (up to 15mg once weekly) is the most effective current pharmacological treatment for obesity, producing up to 21% weight loss. Real-world data shows it outperforms semaglutide. Discuss side effects like nausea with your provider, and consider cost-effectiveness as data is still emerging.
SURMOUNT-1... percentage change in body weight compared to the baseline was... 20.9% with tirzepatide 15 mg... Evidence retrieved from systematic reviews and meta-analyses of relevant RCTs in the field have suggested that tirzepatide provides significantly greater body weight reduction compared to GLP-1 receptor agonists... patients assigned to tirzepatide had a significantly greater weight loss compared to those administered semaglutide (15.5% versus 10.3%, respectively)
Why this rating
Supported by large RCTs (SURMOUNT-1) and corroborated by real-world retrospective cohort studies.
Source
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias et al. · Pragmatic and Observational Research · 2024
DOI 10.2147/por.s471476
More from this paper
- Semaglutide 2.4 mg administered subcutaneously once-weekly produces significant body weight reduction (mean 12.2 kg or 11.8%) and improves cardiometabolic parameters in adults with obesity, with real-world evidence confirming efficacy similar to randomized controlled trials.Good
- Liraglutide 3.0 mg administered subcutaneously once daily produces significant but numerically lower weight loss compared to semaglutide and is less cost-effective, though it remains a safe and efficacious option for obesity management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →